Search Results 501-510 of 18870 for Neutrophil

1. MAGIC Ruxolitinib For AGVHD - Mayo Clinic

   * Standard risk cohort: Hematopoietic engraftment with absolute neutrophil count (ANC) ≥ 1000/μL and platelet count ≥20,000. Use of growth factor ...

2. AZD5305 Vs Placebo In Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents - Mayo Clinic

   Absolute neutrophil count ≥ 1.5 × 10^9 /L with no growth factor support in the 28 days prior to randomisation;. Platelet count ≥ 100 × 10^9 /L;. Serum ...

3. High-Dose Radiation Therapy Versus Standard Care in Treating Patients With Pancreatic Cancer That Cannot Be Removed By Surgery - Mayo Clinic

   Absolute neutrophil count (ANC) ≥ 1,500 cells/mm^3; Platelets ≥ 100,000 cells/mm^3; Hemoglobin ≥ 8.0 g/dl (NOTE: The use of transfusion or other ...

4. Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation - Mayo Clinic

   - Absolute neutrophil count (ANC) >= 1,500/mm^3 - Platelet count >= 100,000/mm - Creatinine =< 1.5 x upper limit of normal (ULN) OR calculated (calc ...

5. Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma - Mayo Clinic

   Peripheral absolute neutrophil count (ANC) ≥ 1000/μL;; Platelet count ≥ 100,000/μL (transfusion independent);; Hemoglobin ≥ 8.0 g/dL (may receive RBC ...

6. A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer - Mayo Clinic

   Absolute neutrophil count (ANC) ≥ 1.5 x 10^9 /L;; Hemoglobin ≥ 9.0 g/dL, independent of transfusions for at least 30 days;; Platelet count ≥ 100 x 10^9/L ...

7. Study Treating Patients with Relapsed or Refractory Aggressive B-cell Lymphomas Using Nivolumab with or without Varlilumab - Mayo Clinic

   Absolute neutrophil count (ANC) ≥ 1500/mm^3. Platelet count ≥ 100,000/mm^3. Hemoglobin > 9.0 g/dL. Total bilirubin ≤ 1.5 x upper limit of normal (ULN) ...

8. Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies - Mayo Clinic

   Absolute neutrophil count ≥000/μL;; Hemoglobin ≥ g/dL;; Platelet count ≥5,000/μL;; Total bilirubin ≤.5 x the upper limit of normal (ULN);; Aspartate ...

9. Phase 1 Study to Evaluate the Safety of ATA188 in Subjects With Progressive and Relapsing-Remitting Multiple Sclerosis - Mayo Clinic

   Hemoglobin < 10 g/dL; platelet < 100×109/L; absolute neutrophil count < 1.5×109/L. Any contraindication to MRI and/or Gd, eg, any object that is reactive to ...

10. A Study to Evaluate Itacitinib for Low Risk Graft-vs-Host Disease (GVHD) - Mayo Clinic

    Use of growth factor supplementation to maintain neutrophil count is allowed. Direct bilirubin must be < 2 mg/dL unless the elevation is known to be due to ...